Want to see SE:CARA full AI Analyst Report?
Top Page
Carasent AB
(CARA)
Select Model
Select Model
Rating:65Neutral
Price Target:
kr29.00
▲(0.00% Upside)
Action:Reiterated
Date:07/11/26
The score is primarily supported by improving profitability and cash generation alongside a very low-leverage balance sheet. This is tempered by a relatively weak valuation (high P/E with no dividend support) and only moderately constructive technicals, with price still below the 200-day average.
Positive Factors
Return to profitability
The return to positive earnings marks a meaningful recovery in operating performance after the loss-making 2023–2024 period. Positive EBITDA and net margins improve internal funding capacity, support product investment, and provide a stronger base for sustaining the healthcare software business.
Negative Factors
Decelerating revenue growth
Current revenue growth remains positive but is materially slower than in earlier high-growth years. Sustained deceleration could limit operating leverage, reduce the pace of customer and market expansion, and make future earnings improvement more dependent on efficiency gains rather than broadening demand.
Read all positive and negative factors
Positive Factors
Negative Factors
Return to profitability
The return to positive earnings marks a meaningful recovery in operating performance after the loss-making 2023–2024 period. Positive EBITDA and net margins improve internal funding capacity, support product investment, and provide a stronger base for sustaining the healthcare software business.
Read all positive factors
Carasent AB (CARA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr1.75B
Dividend Yield15.83%
Average Volume (3M)102.57K
Price to Earnings (P/E)41.8
Beta (1Y)0.15
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees236
SectorGeneral
Sector StrengthN/A
IndustrySoftware - Application
Share Statistics
EPS (TTM)0.62
Shares Outstanding70,324,780
10 Day Avg. Volume40,119
30 Day Avg. Volume102,567
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)2.36
Price to Sales (P/S)5.54
P/FCF Ratio-4.00K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.34
Revenue Forecast (FY)kr414.23M
Carasent AB Business Overview & Revenue Model
Company Description
Carasent AB (publ) provides cloud based electronic health record (EHR) systems solutions and platform services for healthcare sector in Nordics and Germany. The company offers Webdoc, Webcur, Metodika, Ad Curis, Ad Opus, and Data-AL solutions. It ...
How the Company Makes Money
Carasent primarily makes money by selling access to its healthcare software products and related services to healthcare organizations. The core revenue model is typically based on recurring fees for software usage (e.g., subscriptions/SaaS-style l...
Carasent AB Financial Statement Overview
Summary
Income Statement
71
Positive
Balance Sheet
86
Very Positive
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 363.88M | 343.82M | 266.90M | 243.98M | 195.26M | 137.13M |
| Gross Profit | 252.44M | 289.00M | 225.64M | 197.77M | 161.42M | 112.90M |
| EBITDA | 81.40M | 73.34M | 16.99M | 2.91M | 58.81M | 17.91M |
| Net Income | 43.35M | 34.67M | -40.97M | -46.45M | 31.17M | -148.00K |
Balance Sheet | ||||||
| Total Assets | 973.10M | 941.01M | 1.04B | 1.09B | 1.37B | 1.30B |
| Cash, Cash Equivalents and Short-Term Investments | 51.43M | 139.48M | 254.05M | 373.88M | 694.83M | 882.77M |
| Total Debt | 28.66M | 31.94M | 39.95M | 50.17M | 38.88M | 16.34M |
| Total Liabilities | 180.63M | 133.00M | 173.97M | 138.24M | 144.30M | 129.54M |
| Stockholders Equity | 792.47M | 808.00M | 865.73M | 955.41M | 1.23B | 1.17B |
Cash Flow | ||||||
| Free Cash Flow | 51.09M | -476.00K | -4.99M | -73.67M | -57.95M | -5.75M |
| Operating Cash Flow | 91.92M | 40.44M | 36.58M | -4.47M | 33.61M | 32.48M |
| Investing Cash Flow | -131.12M | -35.98M | -116.42M | -55.53M | -209.50M | -125.12M |
| Financing Cash Flow | -162.28M | -122.22M | -15.88M | -263.28M | -10.20M | 756.56M |
Carasent AB Technical Analysis
Neutral
29.00
Price Trends
25.80
Positive
24.57
Positive
24.55
Positive
Market Momentum
0.08
Positive
49.01
Neutral
35.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CARA, the sentiment is Neutral. The current price of 29 is above the 20-day moving average (MA) of 26.24, above the 50-day MA of 25.80, and above the 200-day MA of 24.55, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 49.01 is Neutral, neither overbought nor oversold. The STOCH value of 35.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:CARA.
Carasent AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | kr479.89M | 21.18 | ― | 7.55% | 10.39% | 30.32% | |
71 Outperform | kr3.27B | 27.90 | 32.94% | 1.70% | 8.48% | 19.59% | |
67 Neutral | kr11.08B | 23.40 | 9.37% | 1.33% | 5.39% | 16.79% | |
65 Neutral | kr1.75B | 41.77 | ― | 15.83% | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | kr494.48M | -24.64 | ― | ― | 21.86% | 74.32% |
* General Sector Average
SE:CARA
Carasent AB
26.00
-0.25
-0.95%
SE:DONE
24SevenOffice
6.99
-0.63
-8.27%
SE:LIME
Lime Technologies AB
244.00
-71.07
-22.56%
SE:VIT.B
Vitec Software Group AB Class B
271.60
-63.70
-19.00%
SE:UPSALE
Upsales Technology AB
28.70
-1.26
-4.20%
SE:ONEF
Oneflow AB
18.55
-8.75
-32.05%
Carasent AB Corporate Events
Carasent lifts revenue and margins as cash flow strengthens in first half 2026
Jul 10, 2026
Carasent AB reported solid top-line growth in the second quarter of 2026, with net revenue rising 18% to 97.7 MSEK and annual recurring revenue reaching 395 MSEK, driven mainly by subscription-based sales and low customer churn. Profitability impr...
Carasent to Present Q2 2026 Results via Webcast and Teleconference
Jul 3, 2026
Carasent AB will publish its interim report for the second quarter of 2026 on July 10, 2026 at 07:00 CEST, marking the latest update on the company’s financial and operational performance. The announcement underscores an important disclosure...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.